SCHEMBL5367144

SCHEMBL5367144

NC(=O)COc1ccc(S(=O)(=O)Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
POLB P06746 2/20 0.49
BLM P54132 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
KDM4E B2RXH2 1/20 0.46
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
TBXAS1 P24557 1/20 0.46
RAB9A P51151 1/20 0.45
GAA P10253 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
MAPT P10636 2/20 0.43
ACACA Q13085 1/20 0.42
MAPK1 P28482 1/20 0.41
LMNA P02545 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5316483 0.84 ALDH1A1 (0.73) ALDH1A1KMT2AMEN1TBXAS1MAPT
SCHEMBL9357057 0.84 ALDH1A1 (0.53) ALDH1A1TDP1KMT2AMEN1GAA
SCHEMBL7012916 0.83 POLB (0.47) ALDH1A1POLBKMT2AMEN1LMNA
SCHEMBL10506137 0.82 MEN1 (0.58) ALDH1A1POLBBLMTDP1KDM4E
SCHEMBL4504044 0.79 ALDH1A1 (0.62) ALDH1A1POLBKDM4EGAANPSR1
SCHEMBL7227121 0.79 POLB (0.55) ALDH1A1POLBKMT2AMEN1RAB9A
SCHEMBL5362471 0.78 ALDH1A1 (0.48) ALDH1A1KDM4EKMT2AMEN1GAA
SCHEMBL10468820 0.77 GPR174 (0.48) ALDH1A1POLBKDM4EKMT2AMEN1
SCHEMBL1816835 0.77 SMN1; SMN2 (0.58) ALDH1A1POLBBLMTDP1KMT2A
SCHEMBL2346864 0.77 GAA (0.77) ALDH1A1POLBKDM4ETBXAS1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746966-A1 4-AMINO-2,6-BIS(PHENYLMETHYLENE)CYCLOHEXANONES AND THEIR USE Ustav Organicke Chemie a Biochemie AV CR, v.v.i. (CZ) 2026-05-27 EP disclosed
WO-2025021236-A1 4-AMINO-2,6-BIS(PHENYLMETHYLENE)CYCLOHEXANONES AND THEIR USE Ustav Organicke Chemie A Biochemie AV CR v.v.i. (CZ) 2025-01-30 WO disclosed
US-7294716-B2 Process for preparing isomerically pure prodrugs of proton pump inhibitors ALLERGAN, INC. (US) 2007-11-13 US disclosed
US-7294716-B2 Process for preparing isomerically pure prodrugs of proton pump inhibitors ALLERGAN, INC. (US) 2007-11-13 US disclosed
US-7294716-B2 Process for preparing isomerically pure prodrugs of proton pump inhibitors ALLERGAN, INC. (US) 2007-11-13 US disclosed
EP-1644352-A1 PROCESS FOR PREPARING ISOMERICALLY PURE PRODRUGS OF PROTON PUMP INHIBITORS Allergan, Inc. (US) 2006-04-12 EP disclosed
WO-2005016917-A1 PROCESS FOR PREPARING ISOMERICALLY PURE PRODRUGS OF PROTON PUMP INHIBITORS ALLERGAN, INC. (US) 2005-02-24 WO disclosed
US-20050038076-A1 Process for preparing isomerically pure prodrugs of proton pump inhibitors ALEVIUM PHARMACEUTICALS, INC. 2005-02-17 US disclosed
US-6559167-B1 Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under REGENTS OF THE UNIVERSITY OF CALIFORNIA 2003-05-06 US disclosed
EP-1105387-B1 PRODRUGS OF PROTON PUMP INHIBITORS WINSTON PHARMATEUTICALS LLC (US) 2003-01-29 EP disclosed
EP-1105387-A1 PRODRUGS OF PROTON PUMP INHIBITORS Partnership of Michael E. Garst, George Sachs and Jai Moo Shin (US) 2001-06-13 EP disclosed
WO-2000009498-A1 PRODRUGS OF PROTON PUMP INHIBITORS PARTNERSHIP OF MICHAEL E. GARST, GEORGE SACHS AND JAI MOO SHIN (US) 2000-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038076-A1 Process for preparing isomerically pure prodrugs of proton pump inhibitors SI, ATP6AP1, HRH2 ALDH1A1 1650/4885POLB 1255/4885BLM 3791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.